Leading into Budget week in Canberra this week, was a journey in planning, months in advance by member based groups, to advocate for new policy and funding changes in the Australian Health System.
Some paths are taken because of new crises to be addressed in the workforce, others in considering new models of care to treat patients, or simply to get new medications onto the PBS.
Australian Health Journal met with a number of industry heads after the budget on their journeys so far in lobbying for change, their achievements, some of the disappointments and their thoughts on the road ahead, with an election round the corner.
Skip ahead:
00:35 Tegan Carrison, Executive Director Australian Association of Psychologists Inc (AAPi)
03:12 John Bruning, CEO Australasian College of Paramedicine (ACP)
09:09 Paul Sadler, CEO Aged and Community Services Australia (ACSA)
12:06 Karen Booth, President Australian Primary Health Care Association (APNA)
19:45 Jo Armstrong, CEO Cystic Fibrosis Australia
23:25 Elizabeth de Somer, CEO Medicines Australia
-
National Cancer Plan activates Australian Comprehensive Cancer Network
The landscape of cancer care in Australia is set to transform with the Australian Government launch in May 2024 of the Australian Comprehensive Cancer Network (ACCN) at the Innovations Showcase event, hosted by Cancer Australia in Sydney, Australia.
The ACCN is a nationally integrated system of cancer care, aimed at enhancing patient experiences and outcomes through coordinated and equitable access, by linking to comprehensive cancer services across Australia. Anchored by Comprehensive Cancer Centres (CCCs), the ACCN strives to deliver evidence-driven prevention, diagnosis, treatment, and support to all Australians affected by cancer.
-
Medical device regulations evolve for Australian innovators with European ambitions
Medical device regulation is undergoing significant change as regulators across major jurisdictions grapple with the rapid growth of software and artificial intelligence (AI) in healthcare.
Speaking with Australian Health Journal at the Medical Technology Association of Australia’s RegConnect Summit 2026 in Sydney in September, Gabrielle Cesvet, Head of Public Affairs at Scarlet, said manufacturers need greater clarity and sufficient lead time as new regulatory frameworks emerge.
-
Op-Ed: CGT and proposed RDTI changes creating uncertainty in life sciences
Proposed Budget changes to the Research and Development Tax Incentive (RDTI) will disproportionally impact Australia’s biotech, medtech and health tech sector forcing more home-grown companies to consider moving overseas.
